DF/HCC Timely Special Opportunity (TSO) Awards
Timely Special Opportunity (TSO) Awards enable program leaders and core directors to receive funding quickly for new time-sensitive research, technology development, or purchase of equipment that will contribute to the mission of DF/HCC. The TSO is a one-time award of up to $10,000 and includes full institutional indirect costs.
New TSO Awards:
- High Throughput Isolation of Nucleic Acids from Paraffin-Embedded Tissues
PI: Jon Aster, MD, PhD (BWH)
This TSO award will be used to help the Specialized Histopathology Services Core (SHP) purchase a Qiagen BioRobot Universal System, which has the capacity to isolate nucleic acids in 96-well format. This automated system, which SHP has been beta-testing, will benefit investigators using FFPE samples from the Nurses’ Health Study and Physicians’ Health Study, and will be of broad interest to all investigators using the SHP for tissue microarray construction.
- Quality of Life Implications of Osteonecrosis of the Jaw in Cancer Patients
PI: G. Scott Gazelle, MD, PhD (MGH)
Co-PIs: Rebecca Miksad, MD and J. Shannon Swan, MD
This project is the first evaluation of the impact of osteonecrosis of the jaw (ONJ) on quality of life of cancer patients. More information on ONJ - an adverse effect of intravenous bisphosphonate use in treating patients with breast cancer, prostate cancer, and multiple myeloma - will be valuable to patients and clinicians making treatment decisions, and to policy-makers formulating bisphosphonate treatment guidelines.